IL140910A - An oral pharmaceutical preparation of a compound with antifungal activity and a method of preparation - Google Patents
An oral pharmaceutical preparation of a compound with antifungal activity and a method of preparationInfo
- Publication number
- IL140910A IL140910A IL14091099A IL14091099A IL140910A IL 140910 A IL140910 A IL 140910A IL 14091099 A IL14091099 A IL 14091099A IL 14091099 A IL14091099 A IL 14091099A IL 140910 A IL140910 A IL 140910A
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical composition
- oral pharmaceutical
- compound
- hydrophilic polymer
- inert core
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 20
- 230000000843 anti-fungal effect Effects 0.000 title claims abstract description 19
- 239000008203 oral pharmaceutical composition Substances 0.000 title claims abstract description 15
- 238000000034 method Methods 0.000 title claims description 20
- 238000002360 preparation method Methods 0.000 title description 4
- 238000000576 coating method Methods 0.000 claims abstract description 22
- 239000011248 coating agent Substances 0.000 claims abstract description 18
- 229920001477 hydrophilic polymer Polymers 0.000 claims abstract description 13
- 238000005507 spraying Methods 0.000 claims abstract description 11
- 239000008188 pellet Substances 0.000 claims abstract description 10
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 9
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims abstract description 6
- 229960004130 itraconazole Drugs 0.000 claims abstract description 6
- 239000002356 single layer Substances 0.000 claims abstract description 6
- HUADITLKOCMHSB-AVQIMAJZSA-N 2-butan-2-yl-4-[4-[4-[4-[[(2s,4r)-2-(2,4-difluorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N(C(C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@H]3O[C@@](CN4N=CN=C4)(OC3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 HUADITLKOCMHSB-AVQIMAJZSA-N 0.000 claims abstract description 5
- 229950005137 saperconazole Drugs 0.000 claims abstract description 5
- 239000002245 particle Substances 0.000 claims abstract description 4
- 229940121375 antifungal agent Drugs 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 12
- 230000008569 process Effects 0.000 claims description 10
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- 235000013681 dietary sucrose Nutrition 0.000 claims description 4
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 4
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 229960004793 sucrose Drugs 0.000 claims description 4
- 239000003429 antifungal agent Substances 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 2
- 150000005215 alkyl ethers Chemical class 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 150000002314 glycerols Chemical class 0.000 claims description 2
- 150000002734 metacrylic acid derivatives Chemical class 0.000 claims description 2
- -1 polyoxyethylene Polymers 0.000 claims description 2
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000011324 bead Substances 0.000 description 11
- 230000002776 aggregation Effects 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000005054 agglomeration Methods 0.000 description 5
- 239000011247 coating layer Substances 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229920002538 Polyethylene Glycol 20000 Polymers 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101100179406 Caenorhabditis elegans iff-1 gene Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES009801539A ES2157731B1 (es) | 1998-07-21 | 1998-07-21 | Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion. |
| PCT/ES1999/000230 WO2000004881A1 (es) | 1998-07-21 | 1999-07-20 | Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL140910A0 IL140910A0 (en) | 2002-02-10 |
| IL140910A true IL140910A (en) | 2004-03-28 |
Family
ID=8304581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14091099A IL140910A (en) | 1998-07-21 | 1999-07-20 | An oral pharmaceutical preparation of a compound with antifungal activity and a method of preparation |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US6737082B1 (de) |
| EP (1) | EP1103252B1 (de) |
| JP (1) | JP4190732B2 (de) |
| KR (1) | KR100572135B1 (de) |
| AT (1) | ATE234077T1 (de) |
| AU (1) | AU750730B2 (de) |
| BG (1) | BG65187B1 (de) |
| BR (1) | BR9912300A (de) |
| CA (1) | CA2337509C (de) |
| CZ (1) | CZ291938B6 (de) |
| DE (1) | DE69905905T2 (de) |
| DK (1) | DK1103252T3 (de) |
| EE (1) | EE04415B1 (de) |
| ES (2) | ES2157731B1 (de) |
| HK (1) | HK1037531A1 (de) |
| HR (1) | HRP20010128B1 (de) |
| HU (1) | HU228895B1 (de) |
| IL (1) | IL140910A (de) |
| ME (1) | MEP26708A (de) |
| MX (1) | MXPA01000681A (de) |
| NO (1) | NO320054B1 (de) |
| NZ (1) | NZ509886A (de) |
| PL (1) | PL194740B1 (de) |
| PT (1) | PT1103252E (de) |
| RS (1) | RS50063B (de) |
| RU (1) | RU2209628C2 (de) |
| SK (1) | SK283279B6 (de) |
| TR (1) | TR200100177T2 (de) |
| UA (1) | UA64009C2 (de) |
| WO (1) | WO2000004881A1 (de) |
| ZA (1) | ZA200101293B (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69728379T2 (de) * | 1996-01-31 | 2005-02-24 | South Alabama Medical Science Foundation, Mobile | Lebensmittel und vitamin herstellungen mit natürlichem isomeren von reduzierten folaten |
| US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| EA006402B1 (ru) | 1999-12-23 | 2005-12-29 | Пфайзер Продактс Инк. | Комбинация лекарства и целлюлозного полимера, повышающего концентрацию; способ введения лекарства и водный раствор (варианты) |
| FR2842736B1 (fr) * | 2002-07-26 | 2005-07-22 | Flamel Tech Sa | Formulation pharmaceutique orale sous forme d'une pluralite de microcapsules permettant la liberation prolongee de principe(s) actif(s) peu soluble(s) |
| US20040115287A1 (en) * | 2002-12-17 | 2004-06-17 | Lipocine, Inc. | Hydrophobic active agent compositions and methods |
| SI1438960T2 (sl) * | 2003-01-14 | 2013-04-30 | Cimex Pharma Ag | Sestavek itrakonazola, dispergiranega v hidrofilnem polimeru, z izboljšano biorazpoložljivostjo |
| DE60312636T3 (de) * | 2003-01-14 | 2014-12-24 | Acino Pharma Ag | Bioaequivalente Zusammensetzung in der Form einer festen Dispersion enthaltend Itraconazol und ein hydrophiles Polymer |
| FR2852607B1 (fr) * | 2003-03-20 | 2006-07-14 | Procede de fabrication de microspheres de sucre de petite taille, les microspheres susceptibles d'etre obtenues par ce procede et leurs applications | |
| FR2857591B1 (fr) * | 2003-07-17 | 2007-11-02 | Ethypharm Sa | Particules comprenant un principe actif sous forme de co-precipite |
| EP1648467B1 (de) | 2003-07-17 | 2018-03-21 | Janssen Sciences Ireland UC | Verfahren zur herstellung von ein antivirales mittel enthaltenden teilchen |
| FR2883179B1 (fr) | 2005-03-18 | 2009-04-17 | Ethypharm Sa | Comprime enrobe |
| JP5435946B2 (ja) | 2005-08-22 | 2014-03-05 | ジョンズ ホプキンス ユニバーシティ | 疾患を処置するためのヘッジホッグ経路アンタゴニスト |
| CN101283984B (zh) * | 2007-04-12 | 2010-05-26 | 永胜药品工业股份有限公司 | 高生物使用率的经杀真菌剂和聚合物涂覆的核心微粒状物 |
| US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
| CN102781429A (zh) * | 2010-03-05 | 2012-11-14 | 巴斯夫欧洲公司 | 经熔体涂覆的药物剂型 |
| US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
| US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
| US20170246187A1 (en) | 2014-08-28 | 2017-08-31 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
| US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
| MA40982A (fr) * | 2014-11-19 | 2017-09-26 | Biogen Ma Inc | Formulation de bille pharmaceutique comprenant du fumarate de diméthyle |
| JP2018520114A (ja) * | 2015-05-25 | 2018-07-26 | サン ファーマシューティカル インダストリーズ リミテッドＳｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｉｎｄｕｓｔｒｉｅｓ Ｌｔｄ． | イソトレチノインの１日１回経口医薬組成物 |
| US10137111B2 (en) | 2016-08-11 | 2018-11-27 | Adamis Pharmaceuticals Corporation | Drug compositions comprising an anti-parasitic and proton pump inhibitor |
| CA3078723A1 (en) | 2016-11-28 | 2018-05-31 | Nachiappan Chidambaram | Oral testosterone undecanoate therapy |
| US11564910B2 (en) | 2017-12-08 | 2023-01-31 | Adamis Pharmaceuticals Corporation | Drug compositions |
| WO2019208801A1 (ja) * | 2018-04-27 | 2019-10-31 | 凸版印刷株式会社 | 徐放性複合粒子、徐放性複合粒子の製造方法、乾燥粉体及び壁紙 |
| EP4452232A1 (de) * | 2021-12-22 | 2024-10-30 | Palau Pharma, S.L.U. | Multipartikuläre albaconazolzusammensetzung |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4267179A (en) * | 1978-06-23 | 1981-05-12 | Janssen Pharmaceutica, N.V. | Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles |
| US4916134A (en) * | 1987-03-25 | 1990-04-10 | Janssen Pharmacuetica N.V. | 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]me]phenyl]-1-piperazinyl]phenyl]triazolones |
| IE61651B1 (en) * | 1990-07-04 | 1994-11-16 | Zambon Spa | Programmed release oral solid pharmaceutical dosage form |
| PH30929A (en) * | 1992-09-03 | 1997-12-23 | Janssen Pharmaceutica Nv | Beads having a core coated with an antifungal and a polymer. |
| US5567441A (en) * | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
| CN1165291C (zh) * | 1996-05-20 | 2004-09-08 | 詹森药业有限公司 | 具有改进的生物利用度的抗真菌组合物 |
| CN1121860C (zh) * | 1996-05-24 | 2003-09-24 | 先灵公司 | 提高生物利用度的抗真菌组合物 |
| IL127780A0 (en) * | 1996-06-28 | 1999-10-28 | Schering Corp | Oral compositions comprising a triazole antifungal compound |
| DE19626924C2 (de) * | 1996-07-04 | 1999-08-19 | Epazon B V | Gerät zur Bereitstellung eines Atemgases |
| ES2201485T3 (es) | 1997-03-26 | 2004-03-16 | Janssen Pharmaceutica N.V. | Palets que tienen un nucleo recubierto con un agente antifungico y un polimero. |
-
1998
- 1998-07-21 ES ES009801539A patent/ES2157731B1/es not_active Expired - Fee Related
-
1999
- 1999-07-20 RS YUP-39/01A patent/RS50063B/sr unknown
- 1999-07-20 RU RU2001104894/14A patent/RU2209628C2/ru not_active IP Right Cessation
- 1999-07-20 ES ES99931261T patent/ES2194480T3/es not_active Expired - Lifetime
- 1999-07-20 PT PT99931261T patent/PT1103252E/pt unknown
- 1999-07-20 WO PCT/ES1999/000230 patent/WO2000004881A1/es not_active Application Discontinuation
- 1999-07-20 SK SK86-2001A patent/SK283279B6/sk not_active IP Right Cessation
- 1999-07-20 AT AT99931261T patent/ATE234077T1/de active
- 1999-07-20 MX MXPA01000681A patent/MXPA01000681A/es active IP Right Grant
- 1999-07-20 NZ NZ509886A patent/NZ509886A/xx not_active IP Right Cessation
- 1999-07-20 UA UA2001021260A patent/UA64009C2/uk unknown
- 1999-07-20 IL IL14091099A patent/IL140910A/en not_active IP Right Cessation
- 1999-07-20 PL PL99345625A patent/PL194740B1/pl not_active IP Right Cessation
- 1999-07-20 JP JP2000560874A patent/JP4190732B2/ja not_active Expired - Fee Related
- 1999-07-20 BR BR9912300-2A patent/BR9912300A/pt not_active Application Discontinuation
- 1999-07-20 HU HU0103708A patent/HU228895B1/hu not_active IP Right Cessation
- 1999-07-20 EP EP99931261A patent/EP1103252B1/de not_active Expired - Lifetime
- 1999-07-20 DK DK99931261T patent/DK1103252T3/da active
- 1999-07-20 US US09/744,322 patent/US6737082B1/en not_active Expired - Fee Related
- 1999-07-20 TR TR2001/00177T patent/TR200100177T2/xx unknown
- 1999-07-20 AU AU47821/99A patent/AU750730B2/en not_active Ceased
- 1999-07-20 CZ CZ2001175A patent/CZ291938B6/cs not_active IP Right Cessation
- 1999-07-20 KR KR1020017000783A patent/KR100572135B1/ko not_active IP Right Cessation
- 1999-07-20 EE EEP200100041A patent/EE04415B1/xx not_active IP Right Cessation
- 1999-07-20 DE DE69905905T patent/DE69905905T2/de not_active Expired - Lifetime
- 1999-07-20 ME MEP-267/08A patent/MEP26708A/xx unknown
- 1999-07-20 CA CA002337509A patent/CA2337509C/en not_active Expired - Fee Related
-
2001
- 2001-01-17 NO NO20010289A patent/NO320054B1/no not_active IP Right Cessation
- 2001-02-15 ZA ZA200101293A patent/ZA200101293B/en unknown
- 2001-02-21 HR HR20010128A patent/HRP20010128B1/xx not_active IP Right Cessation
- 2001-02-21 BG BG105282A patent/BG65187B1/bg unknown
- 2001-11-27 HK HK01108330A patent/HK1037531A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1103252B1 (de) | Orale pharmazeutische zusammensetzung enthaltend einen wirkstoff mit antimykotischer wirkung und verfahren zu ihrer herstellung | |
| KR0151893B1 (ko) | 항진균제 및 폴리머로 코팅된 코아를 갖는 비드 | |
| CA2307037C (en) | Oral pharmaceutical preparation comprising an antiulcer activity compound, and process for its production | |
| EP1350508B1 (de) | Fungizide Zubereitung und Methoden zu ihrer Herstellung und Verwendung | |
| EP1051174B2 (de) | Gegen magensaft geschützte omeprazol-mikrogranülen, herstellungsverfahren und pharmazeutische zubereitungen | |
| PL190684B1 (pl) | Sposób stabilizowania substancji aktywnych, którymi sa pochodne benzimidazolowe, preparat farmaceutyczny o kontrolowanym uwalnianiu tych substancji aktywnych oraz sposób wytwarzania tego preparatu | |
| PL190566B1 (pl) | Peletka, zawierająca rdzeń pokryty itrakonazolem i polimerem i sposób jej wytwarzania oraz postać dawki farmaceutycznej | |
| SK177598A3 (en) | Oral composition comprising a triazole antifungal compound | |
| CA2290824A1 (en) | Benzimidazole pharmaceutical composition and process of preparation | |
| RU2311906C2 (ru) | Композиция препарата замедленного высвобождения для высвобождения ингибитора секреции кислоты в желудке и способ ее получения | |
| ITMI990454A1 (it) | Composizioni a rilascio controllato di betaistina | |
| WO2004058257A1 (en) | Controlled release formulation comprising benzimidazole derivatives or pharmaceutically acceptable salts thereof with increased stability and method for preparing the same | |
| US20070148240A1 (en) | Oral formulation containing itraconazole and methods for manufacturing and using the same | |
| KR100605235B1 (ko) | 판토프라졸 함유 경질 캡슐 제제 및 그 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |